Key takeaways
- FDA published warning letters to online peptide vendors through 2026, and they are close to identical in structure: same statutes, same reasoning, different sentences quoted from the store.
- Every letter cites the same chain — FD&C Act §§ 201(g)(1) and 201(p) to make the product a new drug, then §§ 301(d) and 505(a) to make selling it a prohibited act.
- The evidence is almost always the vendor’s own product pages. FDA quotes the copy verbatim, which means the sentence you wrote is the sentence in the letter.
- Notably, these letters cite unapproved new drug violations rather than misbranding under § 502(f)(1) — the problem is that the product is a drug at all, not that the label is wrong.
- Reading two or three letters in full is the cheapest compliance education available for this category, and they are free and public.
Why these letters are worth reading yourself
A warning letter is FDA telling a company, in public and in detail, exactly what it found and why that is unlawful. For a category with very little settled guidance, that makes the letters the closest thing to a published rulebook — and they name the URLs, quote the copy and describe the products.
The three letters summarised here were issued on 31 March, 17 June and 24 August 2026. They are linked in full at the bottom of this page. If you run a research-supply store, read at least one of them end to end before you read another summary, including this one.
What follows is a factual read of what those documents say. It is not legal advice, and it is not a list of ways to avoid a letter — the pattern is consistent enough that the only reliable conclusion is about what the store is, not about how it is worded.
The statutory chain, which never varies
Each letter walks the same four steps. Section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act defines a drug by intended use, including articles intended to affect the structure or function of the body. Section 201(p) defines a new drug as one not generally recognized as safe and effective for its labeled use.
Section 505(a) then requires an approved application before a new drug enters interstate commerce, and section 301(d) makes doing so without one a prohibited act. The letters cite the pair together, as “sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)”.
What is absent is as informative as what is present. In all three letters the violation is unapproved new drug — not misbranding under section 502(f)(1) for inadequate directions for use. FDA is not saying the label was wrong. It is saying the article was a drug and should not have been sold at all.
The three letters, side by side
The table sets out what FDA quoted in each case. The middle column is the store’s own published copy, reproduced in the letter.
| Letter | What FDA quoted from the site | What it established |
|---|---|---|
| 31 March 2026 | “[I]nfluences appetite suppression, insulin sensitivity, thermogenesis, and fat-oxidation”; “Associated with significant decreases in body weight in both animal and human studies.” | Structure/function and disease-related effects described for the product, with human studies used as support |
| 17 June 2026 | “reduces chronic inflammation in the prostate, swelling and vascular hyperemia”; “for Enlarged Prostate”; “can improve bladder control, reducing frequency and urgency” | Treatment of a named condition — the clearest form of a drug claim |
| 24 August 2026 | “potential therapeutic applications in various conditions”; “potential research applications in metabolic disorders, particularly obesity and type 2 diabetes”; the sale of “Bacteriostatic water for Peptides (BAC Water)”; a “peptide calculator” | Therapeutic framing plus the means of preparing an injectable dose — the circumstances of sale, not only the copy |
| All three | “RESEARCH USE ONLY”, “not for human consumption” or equivalent disclaimers | Rejected in each case; FDA wrote that despite the statements, website evidence established the products were intended as drugs for human use |
The pattern, in seven items
Reduced to its components, the recurring fact pattern across the published letters looks like this. Every item is something the store chose to publish.
- Outcome language on product pages — appetite, weight, inflammation, a named condition, a bodily function.
- Human studies cited as evidence that the product works, which frames it for human use.
- Hedging words such as “potential” and “research applications” in front of a therapeutic claim, which the letters treat as no defence.
- A research-use or not-for-human-consumption disclaimer, present and unavailing in every case.
- Bacteriostatic water or other reconstitution supplies offered alongside the vials.
- An on-site calculator that, in FDA’s words, “provides the means to prepare an injectable drug”.
- Compounds whose public reputation is a human therapeutic use, presented without anything that would make a laboratory buyer the obvious audience.
What the letters ask a company to do
The closing sections are as standardised as the findings. The company is directed to review its websites, product labels and other labeling and promotional materials to make sure it is not unlawfully marketing unapproved new drugs, and to respond in writing within fifteen working days describing the specific steps it has taken.
A response is expected to explain how the firm will prevent a recurrence, not merely that pages were edited. Where a violation cannot be corrected within the window, the letter asks for the reason and a timetable. FDA also states that the list of violations is not exhaustive and that the company is responsible for finding the rest.
The letters close by noting that failure to address the violations may result in legal action, and they name seizure and injunction. That is the standard formula rather than a prediction, but it is the reason a letter is treated as a serious event rather than correspondence.
What a merchant should take from this
The first conclusion is narrow and practical: the hedge does not work. “Potential therapeutic applications” was quoted in a warning letter as evidence, not treated as a softened claim. Neither did “in animal and human studies”, nor a disclaimer three scroll-lengths down.
The second is broader. Because the violation cited is unapproved new drug rather than misbranding, editing the copy does not by itself resolve what the letters describe. It changes the evidence. Whether the underlying business is a research-supply business is a question about the whole operation — what is in the catalog, who buys it, what is sold next to it, what the reviews say.
The third is about surface area. Two of the three letters quote only product pages. The third reaches into the catalog and the site’s tools. Anything public is in scope: descriptions, FAQs, blog posts, text inside images, email, ads, affiliate copy and customer reviews.
If you want the practical version of this, the guide to product descriptions without claims covers what to write instead, and is it legal to sell research peptides covers the underlying legal test. Torva OS flags health, dosing and drug-brand claims at build, at import and on every save, across product copy, storefront pages, email and affiliate content — you can preview it against your own catalog free.
Frequently asked questions
Where can I read FDA warning letters to peptide companies?
FDA publishes them in a searchable database, linked below. Letters are posted after issue and remain public. Searching the database for peptide vendors turns up the 2026 round discussed here plus earlier actions.
Does hedging a claim with “potential” or “research suggests” help?
The published letters do not support that. An August 2026 letter quoted “potential therapeutic applications in various conditions” and “potential research applications in metabolic disorders” as evidence of intended human use. The hedge was part of the quotation, not a defence to it.
Why do the letters cite 505(a) rather than misbranding?
Because the finding is that the articles are unapproved new drugs, which makes introducing them into interstate commerce a prohibited act under section 301(d) regardless of how they are labeled. Misbranding under 502(f)(1) addresses inadequate directions for use, which is a different problem and was not what these letters alleged.
Are customer reviews and social posts part of the evidence?
FDA has long held that intended use may be shown by labeling, advertising and the circumstances surrounding distribution. The 2026 letters draw on product pages and on what was sold alongside the products. Treat everything publicly attached to your store as potentially in scope.
Sources
Preview your store on Torva OS — no card needed — or explore the Desk demo, the eight themes and the plans. Questions: hello@torvaos.com.
General information for merchants, not legal, tax or financial advice. Check the rules in your jurisdiction and with your providers.